Compare · MO vs VLON
MO vs VLON
Side-by-side comparison of Altria Group Inc. (MO) and Vallon Pharmaceuticals Inc. (VLON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MO and VLON operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $92.73B, about 3058.7x VLON ($30.3M).
- MO has hit the wire 1 time in the past 4 weeks while VLON has been quiet.
- MO has more recent analyst coverage (19 ratings vs 1 for VLON).
- Company
- Altria Group Inc.
- Vallon Pharmaceuticals Inc.
- Price
- $66.89-0.41%
- $12.00+2453.19%
- Market cap
- $92.73B
- $30.3M
- 1M return
- +4.85%
- -
- 1Y return
- +14.95%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 1
- 0
- Recent ratings
- 19
- 1
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Vallon Pharmaceuticals Inc.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Latest MO
- Altria to Host Webcast of 2026 First-Quarter Results
- SEC Form DEFA14A filed by Altria Group Inc.
- SEC Form DEF 14A filed by Altria Group Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Altria Group Inc.
- on! PLUS™ Expands Nationwide Retail Availability
- SVP, Chief HR Off. & CCO Whitaker Charles N. sold $1,885,718 worth of shares (27,908 units at $67.57), decreasing direct ownership by 13% to 180,869 units (SEC Form 4)
- EVP & General Counsel Mccarter Robert A. Iii was granted 5,767 shares and covered exercise/tax liability with 4,517 shares, increasing direct ownership by 1% to 123,612 units (SEC Form 4)
- Chief Executive Officer Gifford William F. Jr. was granted 70,364 shares and covered exercise/tax liability with 61,849 shares, increasing direct ownership by 1% to 681,942 units (SEC Form 4)
- EVP & CFO Mancuso Salvatore was granted 17,166 shares and covered exercise/tax liability with 17,385 shares, decreasing direct ownership by 0.08% to 280,275 units (SEC Form 4)
- Vice President and Controller Patterson Katie F covered exercise/tax liability with 844 shares, decreasing direct ownership by 5% to 17,513 units (SEC Form 4)
Latest VLON
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B4 filed by Vallon Pharmaceuticals Inc.
- SEC Form EFFECT filed by Vallon Pharmaceuticals Inc.
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders